Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation

• Status: Completed
• Trial end date: 2014-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the effectiveness and safety of zoledronic acid with alendronate in the prevention of bone loss after organ transplantation. Zoledronic acid is given as a single intravenous infusion. Alendronate is given as a weekly pill. Both are expected to be very effective, but it is not known which one will work best.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Columbia University
• Collaborator: Novartis Pharmaceuticals
• Treatments: Alendronate; Diphosphonates; Zoledronic Acid

Criteria

Inclusion Criteria:

• A man or woman, aged 20 to 70, of any race who has had a heart or liver transplant

Exclusion Criteria:

• hyperparathyroidism

• Paget's disease

• hyperthyroidism

• cancer

• severe kidney disease,

• intestinal disease

• active peptic ulcer disease

• current or past treatment for osteoporosis

• pregnancy or lactation

• severe oral/dental disease